Evidence map›Paper›PMID 22709754›Full record

Trial reportAmerican heart journal2012

Long-term outcomes after a strategy of percutaneous coronary intervention of the infarct-related artery with drug-eluting stents or bare metal stents vs medical therapy alone in the Occluded Artery Trial (OAT).

Xavier Freixa, Vladimír Džavík, Sandra A Forman, James M Rankin, Christopher E Buller, Warren J Cantor, Witold Ruzyllo, Harmony R Reynolds, Gervasio A Lamas, Judith S Hochman

Erratum issued Registry-linked trialOpen access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in American heart journal, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT00004562 (Occluded Artery Trial), which is not on this map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00004562 phase3completednot on this map

Occluded Artery Trial (OAT) - Randomized Comparative Effectiveness Trial of PCI and Medical Therapy Only Post MI

TypeinterventionalSponsorNYU Langone HealthRan1999 to 2011Enrolled2,201ConditionsCardiovascular Diseases, Heart Diseases, Myocardial Infarction, Heart Failure, CongestiveArmsBeta adrenergic blockers, Platelet inhibitors, PTCA and stents, ACE Inhibitors
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Trial
4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

10 authors at 8 institutions in 4 countries.

Xavier FreixaPeter Munk Cardiac Centre, University Health Network, Toronto, Newmarket, Canada.
Vladimír Džavík
Sandra A Forman
James M Rankin
Christopher E Buller
Warren J Cantor
Witold Ruzyllo
Harmony R Reynolds
Gervasio A Lamas
Judith S Hochman
New York University · USUniversity Health Network · CAClinical Trials and Surveys Corporation · USInstitute of Cardiology · PLMount Sinai Hospital · USRoyal Perth Hospital · AUSouthlake Regional Health Center · CASt. Michael's Hospital · CA

Funding

Occluded Artery Trial: Long Term Follow-UpU01HL062509 · NHLBI · ST. LUKE'S-ROOSEVELT INST FOR HLTH SCIS · PI HOCHMAN, JUDITH S · 1999 to 2010
$11.1M
Occluded Artery Trial: Long-Term Follow up-Data Coordinating CenterU01HL062511 · NHLBI · MARYLAND MEDICAL RESEARCH INSTITUTE, INC · PI FORMAN, SANDRA · 1999 to 2010
$5.2M
ECONOMICS AND QUALITY OF LIFE IN THE OCCLUDED ARTERY TRIU01HL062257 · NHLBI · DUKE UNIVERSITY · PI MARK, DANIEL B · 1999 to 2003
$1.5M
TOSCA-2 An Angiographic Substudy of the Occluded Arter*R01HL067683 · NHLBI · UNIVERSITY HEALTH NETWORK · PI DZAVIK, VLADIMIR · 2001 to 2004
$925k
NHLBI NIH HHS HL67683-01A1NHLBI NIH HHS R01 HL067683NHLBI NIH HHS U01 HL062257NHLBI NIH HHS U01 HL062509NHLBI NIH HHS U01 HL062511
6 · The paper itself

Abstract

backgroundThe OAT, a randomized study of routine percutaneous coronary intervention or optimal medical therapy (MED) alone for the treatment of a totally occluded infarct-related artery in the subacute phase after myocardial infarction, showed similar rates of death, reinfarction and congestive heart failure (CHF) between study groups. Although most percutaneous coronary intervention patients were treated with bare metal stents (BMS), drug-eluting stents (DES) were also implanted in the latter part of the study. The aim of the study was to conduct an exploratory analysis of long-term outcomes for DES vs. BMS deployment vs. MED in the OAT.

methodsPatients enrolled after February 2003 (when first DES was implanted) were followed (DES n = 79, BMS n = 393, MED n = 552) up to a maximum of 6 years (mean survivor follow-up 5.1 years).

resultsThe 6-year occurrence of the composite end point of death, reinfarction and class IV CHF was similar [20.4% of DES, 18.9% of BMS and 18.4% of MED (P = .66)] as were the rates of the components of the primary end point. During the follow-up period, 33.4% of DES, 44.4% of BMS and 48.1% of MED patients, developed angina (P = .037). The rate of revascularization during follow up was 11.3%, 20.5% and 22.5% among these groups, respectively (P = .045).

conclusionsThere is no suggestion of reduced long-term risk of death, reinfarction or class IV CHF with DES usage compared to BMS or medical treatment alone. An association between DES use and freedom from angina and revascularization relative to medical therapy is suggested.

Indexed as

Angioplasty, Balloon, CoronaryStentsAdultAgedAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsCoronary OcclusionDrug-Eluting StentsFemaleFollow-Up StudiesHumansMaleMiddle AgedMyocardial InfarctionAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor Antagonists

Identifiers

PMID22709754
PMCPMC3735135
OpenAlexW2013512316

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.